The National Cancer Institute (NCI) at the National Institutes of Health is currently enrolling participants for a stem cell transplant clinical trial. The phase II/III trial is intended to study an autologous (taken from the person’s own body) peripheral blood stem cell transplant for both non-Hodgkin (NHL) and Hodgkin lymphoma (HL).
According to the Leukemia Research Foundation “Every four minutes, someone is diagnosed with blood cancer – more than 201,870 new cases are expected this year in the United States.” New treatments for blood cancers, such as lymphoma–both NHL and HL–are greatly needed with stem cell therapies hopefully accounting as one solution. By using autologous cells taken from an individual’s own body, clinicians can prevent rejection of the transplant.
The main objectives of the study will be to measure if the transplant improves survival in people with these types of lymphomas and also to determine whether the treatment is ultimately safe for both people with HIV infection and those with relapsed cancer. Participants will be individuals with NHL or HL who are under the age of 70 and hematologist Dr. Veronika Bachanova of the University of Minnesota will lead the study.
The study has been ongoing since 2005, however the investigators are currently admitting more participants and they estimate the trial will completed by December of 2016. In total, the team plans to study 325 individuals using this stem cell approach.
People who are interesting in participating in this study can contact:
Email: [email protected]
For the full article click here